+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Immune tolerance in mucopolysaccharidosis I patients after long term enzyme replacement therapy



Immune tolerance in mucopolysaccharidosis I patients after long term enzyme replacement therapy



Journal of Inherited Metabolic Disease 26(Suppl. 2): 140




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035084889

Download citation: RISBibTeXText


Related references

Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 361(9369): 1608-1613, 2003

Long-term effects of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis IVA. Pediatrics and Neonatology 2018, 2018

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series. Molecular Genetics and Metabolism Reports 7: 63-69, 2016

Bull's eye maculopathy and subfoveal deposition in two mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. American Journal of Ophthalmology Case Reports 9: 1-6, 2018

Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. Journal of Clinical Investigation 118(8): 2868-2876, 2008

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I. Molecular Therapy. Methods and Clinical Development 13: 321-333, 2019

Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Proceedings of the National Academy of Sciences of the United States of America 101(3): 829-834, 2004

Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Molecular Genetics and Metabolism 114(2): 129-137, 2015

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Inherited Metabolic Disease 33(1): 51-60, 2010

Long-term enzyme replacement therapy of canine mucopolysaccharidosis I. Pediatric Research 37(4 PART 2): 149A, 1994

Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation. Biochimica et Biophysica Acta 1862(9): 1608-1616, 2016

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy. Journal of Inherited Metabolic Disease 36(2): 385-394, 2014

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients. Molecular Genetics and Metabolism Reports 12: 2-7, 2017

Long-term and high dose enzyme replacement therapy in the canine mucopolysaccharidosis I model. American Journal of Human Genetics 57(4 SUPPL ): A39, 1995

Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome). European Review for Medical and Pharmacological Sciences 15(3): 253-258, 2011